Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8737269 | Diagnostic Microbiology and Infectious Disease | 2018 | 29 Pages |
Abstract
This study evaluated the performance of the Altona Diagnostics RealStar® Adenovirus Research Use Only (RUO) real-time PCR reagents for HAdV quantitation in plasma samples from immunodeficient patients. The assay was linear from 2.30-9.17 log10 copies/mL (coefficient of determination; R2 = 0.998) with limits of detection and quantification of 2.19 log10 and 2.30 log10 copies/mL (>95% positivity rate), respectively. Assay precision was highly reproducible with coefficients of variance ranging from 0% to 4.7%. A comparison of 66 matched samples showed good agreement (R2 = 0.845) between the Altona and the reference laboratory assay, with an average negative bias (â0.24 log10 copies/mL). Genotyping analysis demonstrated that HAdV species B and C accounted for 77% of the positive samples. A significant (â¥0.9 log10) difference in quantitation between both tests was found for three HAdV types (HAdV types A12, B14 and F41). In conclusion, the Altona RealStar® test is a reliable and sensitive assay for HAdV DNA quantitation.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Hanna Rennert, Girish Ramrattan, Zhengming Chen, Patrick McIntire, Alber Michaeel, Anna Khazanova, Stephen G. Jenkins, John Sipley,